Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 68

Sort by

Sort Order Select

Journal Articles

Male-Biased Spliceosome Mutations in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Impair pDC Activation and Apoptosis

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-137727

Published: 2020

Journal Articles

Individualized Mitochondrial Functional Approach to Combination of BCL-2 and MCL-1 Antagonism in Acute Myeloid Leukemia

Shruti Bhatt, PhD, Marissa Pioso, Elyse Ann Olesinski, Binyam Yilma, Leutz Buon, Sophia Adamia, PhD, Holly Zhu, Jeremy Ryan, Youzhen Wang, Morris Erick, Ensar Halilovic, David M. Weinstock, MD, Jacqueline S Garcia, MD, Anthony Letai

Blood (2019) 134 (Supplement_1): 2551.

https://doi.org/10.1182/blood-2019-131101

Published: 2019

Journal Articles

Co-Expression of SYK and ZAP70 Subverts Negative B-Cell Selection and Enables Oncogenic Signaling in Multiple B-Cell Malignancies

Teresa Sadras, PhD, Mickaël Martin, MD PhD, Lauren Kim-Sing, Jevon Cutler, PhD, Gal Lenz, PhD, Anne Marie Knapp, Dana Ghergus, MD PhD, Fabien Delmotte, Cédric Schleiss, Anne-Sophie Korganow, MD PhD, Pauline Soulas-Sprauel, PharmD, PhD, Zhengshan Chen, MD PhD, Akhilesh Pandey, MD PhD, David M. Weinstock, MD, Hassan Jumaa, PhD, Eric Meffre, PhD, Thierry Martin, MD PhD, Markus Müschen, MD PhD

Blood (2019) 134 (Supplement_1): 295.

https://doi.org/10.1182/blood-2019-128999

Published: 2019

Journal Articles

Dynamic Assembly of a Feedback Complex to Regulate Oncogenic B-Cell Receptor-Signaling

Blood (2019) 134 (Supplement_1): 393.

https://doi.org/10.1182/blood-2019-131270

Published: 2019

Journal Articles

DT2216, a BCL-XL Proteolysis Targeting Chimera (PROTAC), Is a Potent Anti T-Cell Lymphoma Agent That Does Not Induce Significant Thrombocytopenia

Yonghan He, MD, Raphael Koch, Vivekananda Budamagunta, Dongwen Lv, Sajid Khan, Xuan Zhang, Janet S Wiegand, Guangrong Zheng, David M. Weinstock, MD, Daohong Zhou

Blood (2019) 134 (Supplement_1): 303.

https://doi.org/10.1182/blood-2019-125820

Published: 2019

Journal Articles

Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 4019.

https://doi.org/10.1182/blood-2019-125017

Published: 2019

Journal Articles

Enhancer Rewiring Dependent Switch from BCL2 to MCL1 Dependency Predicts NOTCH1 Inhibition Response in T-ALL

Valeriya Dimitrova, Huiyoung Yun, PhD, Sayalee Potdar, Alexandria Nicole Van Scoyk, BS, Shruti Bhatt, PhD, Praveen Anand, PhD, Monica S. Nair, Jake A. Kloeber, Antonis Kokkalis, PhD MSc, Julia Frede, PhD MPhil, Johannes M. Waldschmidt, MD, Anthony G. Letai, MD PhD, David M. Weinstock, MD, Jon C. Aster, MD PhD, Jens G. Lohr, MD PhD, Birgit Knoechel, MD PhD

Blood (2019) 134 (Supplement_1): 3948.

https://doi.org/10.1182/blood-2019-131148

Published: 2019

Journal Articles

A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for Untreated BCR-ABL1-Positive ALL in Older Adults

Marlise Luskin, MDMS, Mark A. Murakami, MDMA,MMSc, Kristen E. Stevenson, MS, Martha Wadleigh, MD, Malgorzata McMasters, MD, Peter Winter, PhD, David M. Weinstock, MD, Richard Stone, MD, Daniel J. DeAngelo, MD PhD

Blood (2019) 134 (Supplement_1): 3879.

https://doi.org/10.1182/blood-2019-125138

Published: 2019

Journal Articles

A Clinically-Indolent Variant of Extranodal NK/T Cell Lymphoma with Unique Immunophenotypic Profile and Superior Outcome

Fabiola Valvert, MD, Elizabeth Solorzano, MSc, Edward Briercheck, MD, Marcos Mauricio Siliézar Tala, MD, Yasodha Natkunam, MD PhD, David M. Weinstock, MD, Oscar Silva, MD PhD

Blood (2019) 134 (Supplement_1): 5278.

https://doi.org/10.1182/blood-2019-131620

Published: 2019

Journal Articles

Durable Responses Observed with JAK Inhibition in T-Cell Lymphomas

Alison J. Moskowitz, MD, Eric Jacobsen, MD, Jia Ruan, MD PhD, Jonathan H. Schatz, MD, Obadi Obadi, Kristin Motylinski, Christine Jarjies, MS, Natasha Galasso, Helen Hancock, NP, Theresa Davey, MPAS, Patricia Myskowski, MD, Ahmet Dogan, MD PhD, Giorgio Inghirami, MD, David M Weinstock, MD, Steven M. Horwitz, MD

Blood (2018) 132 (Supplement 1): 2922.

https://doi.org/10.1182/blood-2018-99-112123

Published: 2018

Journal Articles

Preliminary Results of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Two Phase IIa Dose Expansion Cohorts in Relapsed/Refractory TP53 Wild-Type Peripheral T-Cell Lymphoma

Andrei R. Shustov, MD, Steven M. Horwitz, MD, Jasmine Zain, MD, Manish R Patel, MD, Sanjay Goel, MD, Lubomir Sokol, MD PhD, Funda Meric-Bernstam, MD, Geoffrey Shapiro, MD PhD, Sunita Dwivedy Nasta, MD, Murali Janakiram, MD MS, David M Weinstock, MD, Ronald Korn, MD PhD, Marie Payton, MBA, D. Allen Annis, PhD, Dawn Pinchasik, MD, Manuel Aivado, MD PhD, Amitkumar Mehta, MD

Blood (2018) 132 (Supplement 1): 1623.

https://doi.org/10.1182/blood-2018-99-116780

Published: 2018

Journal Articles

Triple Degradation of BTK, IKZF1 and IKZF3 in B-Cell Malignancies

Sara Morrow, BA, Dennis Dobrovolsky, PhD, Eric Wang, PhD, Radosław P. Nowak, PhD, Katherine Donovan, PhD, Tyler Faust, PhD, Guang Yang, PhD, Zhengnian Li, PhD, Eric Fischer, Steven P Treon, MD PhD FRCP, David M Weinstock, MD, Nathanael S. Gray, PhD

Blood (2018) 132 (Supplement 1): 263.

https://doi.org/10.1182/blood-2018-99-116895

Published: 2018

Journal Articles

Targeted Inhibition of CD47-Sirp Alpha Requires Fc-Fc Gamma Receptor Interactions to Maximize Phagocytosis in T-Cell Lymphomas

Salvia Jain, MD, Alexandria Van Scoyk, Elizabeth A Morgan, MD, Andrew Matthews, MD, Kristen E. Stevenson, MS, Gail Newton, PhD, Anu K Autio, PhD, Marisa O. Peluso, MS, Rachel W O'Connor, BS, Alison M. Paterson, PhD, Pamela M. Holland, PhD, Francis W Luscinskas, PhD, David M Weinstock, MD

Blood (2018) 132 (Supplement 1): 339.

https://doi.org/10.1182/blood-2018-99-112986

Published: 2018

Journal Articles

CD25-Dependent Feedback Control of the B-Cell Receptor and Its Oncogenic Mimics in B-Cell Malignancies

Blood (2018) 132 (Supplement 1): 776.

https://doi.org/10.1182/blood-2018-99-117553

Published: 2018

Journal Articles

The Combination of Duvelisib, a PI3K-δ,γ Inhibitor, and Romidepsin Is Highly Active in Relapsed/Refractory Peripheral T-Cell Lymphoma with Low Rates of Transaminitis: Results of Parallel Multicenter, Phase 1 Combination Studies with Expansion Cohorts

Blood (2018) 132 (Supplement 1): 683.

https://doi.org/10.1182/blood-2018-99-115241

Published: 2018

Journal Articles

Ultra-Sensitive Detection of Circulating Serum microRNAs (miRNAs) in Diffuse Large B-Cell Lymphoma (DLBCL) Patient-Derived Xenograft (PDX) Models and Correlation with Disease Status in DLBCL Patient

Afshin Beheshti, PhD, Kristen E. Stevenson, MS, Ravi Dashnamoorthy, PhD, Charles Vanderburg, PhD, David M Weinstock, MD, Andrew M. Evens, DO, MSc

Blood (2018) 132 (Supplement 1): 2973.

https://doi.org/10.1182/blood-2018-99-116789

Published: 2018

Journal Articles

In Vitro andpre-Clinical In Vivo evidence Support MDMX/MDM2 As Common Vulnerabilities across TP53 -Wild-Type T-Cell Lymphomas That Are Targetable with the α-Helical p53 Stapled Peptide Alrn-6924

Raphael Koch, MD, Amanda L Christie, BS, Noriaki Yoshida, MD PhD, Samuel Y. Ng, MDPhD, Kay Shigemori, Sara N Morrow, Alexandria Van Scoyk, Steven M. Horwitz, MD, Eric Jacobsen, MD, Solimar Santiago, Jian-Guo Ren, Vincent Guerlavais, PhD, D. Allan Annis, Manuel A. Aivado, MD PhD, David M. Weinstock, MD

Blood (2017) 130 (Supplement 1): 571.

https://doi.org/10.1182/blood.V130.Suppl_1.571.571

Published: 2017

Journal Articles

Generation and Application of T-Cell Lymphoma Patient Derived Tumor Xenograft Models

Blood (2017) 130 (Supplement 1): 109.

https://doi.org/10.1182/blood.V130.Suppl_1.109.109

Published: 2017

Journal Articles

An Off-the-Shelf™ Fratricide-Resistant CAR-T for the Treatment of T Cell Hematologic Malignancies

Blood (2017) 130 (Supplement 1): 844.

https://doi.org/10.1182/blood.V130.Suppl_1.844.844

Published: 2017

Journal Articles

A Functional Approach to Precision Medicine Identifies Targeted Therapies for Acute Myeloid Leukemia

Shruti Bhatt, PhD, Vineeth Kumar Murali, Holly Zhu, Sophia Adamia, PhD, Amanda L Christie, BS, David M. Weinstock, MD, Jackie S Garcia, MD, Anthony Letai, MD PhD

Blood (2017) 130 (Supplement 1): 853.

https://doi.org/10.1182/blood.V130.Suppl_1.853.853

Published: 2017

NARROW

Male-Biased Spliceosome Mutations in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Impair pDC Activation and Apoptosis

Individualized Mitochondrial Functional Approach to Combination of BCL-2 and MCL-1 Antagonism in Acute Myeloid Leukemia

Co-Expression of SYK and ZAP70 Subverts Negative B-Cell Selection and Enables Oncogenic Signaling in Multiple B-Cell Malignancies

Dynamic Assembly of a Feedback Complex to Regulate Oncogenic B-Cell Receptor-Signaling

DT2216, a BCL-XL Proteolysis Targeting Chimera (PROTAC), Is a Potent Anti T-Cell Lymphoma Agent That Does Not Induce Significant Thrombocytopenia

Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma

Enhancer Rewiring Dependent Switch from BCL2 to MCL1 Dependency Predicts NOTCH1 Inhibition Response in T-ALL

A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for Untreated BCR-ABL1-Positive ALL in Older Adults

A Clinically-Indolent Variant of Extranodal NK/T Cell Lymphoma with Unique Immunophenotypic Profile and Superior Outcome

Durable Responses Observed with JAK Inhibition in T-Cell Lymphomas

Preliminary Results of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Two Phase IIa Dose Expansion Cohorts in Relapsed/Refractory TP53 Wild-Type Peripheral T-Cell Lymphoma

Triple Degradation of BTK, IKZF1 and IKZF3 in B-Cell Malignancies

Targeted Inhibition of CD47-Sirp Alpha Requires Fc-Fc Gamma Receptor Interactions to Maximize Phagocytosis in T-Cell Lymphomas

CD25-Dependent Feedback Control of the B-Cell Receptor and Its Oncogenic Mimics in B-Cell Malignancies

The Combination of Duvelisib, a PI3K-δ,γ Inhibitor, and Romidepsin Is Highly Active in Relapsed/Refractory Peripheral T-Cell Lymphoma with Low Rates of Transaminitis: Results of Parallel Multicenter, Phase 1 Combination Studies with Expansion Cohorts

Ultra-Sensitive Detection of Circulating Serum microRNAs (miRNAs) in Diffuse Large B-Cell Lymphoma (DLBCL) Patient-Derived Xenograft (PDX) Models and Correlation with Disease Status in DLBCL Patient

In Vitro andpre-Clinical In Vivo evidence Support MDMX/MDM2 As Common Vulnerabilities across TP53 -Wild-Type T-Cell Lymphomas That Are Targetable with the α-Helical p53 Stapled Peptide Alrn-6924

Generation and Application of T-Cell Lymphoma Patient Derived Tumor Xenograft Models

An Off-the-Shelf™ Fratricide-Resistant CAR-T for the Treatment of T Cell Hematologic Malignancies

A Functional Approach to Precision Medicine Identifies Targeted Therapies for Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only